High-dose (HD) bolus IL-2 therapy is one of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment. Because HD IL-2-associated toxicity is severe, it would be beneficial for clinicians to determine if a patient would respond ...
Read MoreYou have just read an article categorized health
titled How to Predict the Outcome for High-Dose IL-2 Therapy in Cancer Patients.
Written by:
editor - Tuesday, December 3, 2013
There are currently no comments for "How to Predict the Outcome for High-Dose IL-2 Therapy in Cancer Patients"
Post a Comment